Price: 6500 INR/Piece
Bortezomib falls in the category of proteasome inhibitors. It is indicated for multiple myeloma and mantle-cell lymphoma. The medicine inhibits the production of proteins that are important for the growth and multiplication of cancer cells. In addition, the medicine also blocks the action of proteasome and slows down the rate of growth of cancerous actively growing cells. It is recommended as a targeted therapy and also given after other cancer medications have been unsuccessful.